{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:32Z","timestamp":1791908312485,"version":"4.3.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure with reduced ejection fraction (HFrEF) represents a severe manifestation or terminal stage of various cardiac diseases. Long-term hypertension frequently leads to pathological changes such as ventricular remodeling, resulting in HFrEF. Despite continuous advancements in medications targeting hypertension complicated by HFrEF, the five-year survival rate for patients remains below 50%. Chinese Medicine (CM) demonstrates favorable long-term efficacy in managing HFrEF and reducing readmission rates. Focusing on the primary symptoms of HFrEF, we innovatively proposed the syndrome pattern \u201cToxic Pathogen Syndrome\u201d and developed the effective compound formula Qi Shen Granules (QSG). This trial aims to conduct a prospective clinical study to evaluate the efficacy and safety of QSG in patients with hypertension and HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial. A total of 220 eligible participants with hypertension and HFrEF will be recruited and randomized in a 1:1 ratio to receive either QSG or placebo for 12 weeks. All participants received guideline-directed treatment for hypertension and HFrEF throughout the study period. The primary outcome is the improvement rate in plasma NT-proBNP levels from baseline to endpoint and the six-minute walk test. Secondary outcomes include echocardiographic parameters, NYHA functional class, Kansas City Cardiomyopathy Questionnaire (KCCQ), and Heart Failure Toxicity Scale. Safety measures, including liver and kidney function blood tests and adverse events, were used to assess QSG safety. We also conducted follow-up assessments at weeks 26 and 52 to evaluate patient readmission rates and the occurrence of cardiovascular adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this study may establish clinical evidence supporting the therapeutic benefits and safety of QSG in the management of hypertension with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>http:\/\/itmctr.ccebtcm.org.cn\/<\/jats:ext-link>\n                      , ITMCTR2025000665.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1897966","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:28Z","timestamp":1788759208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term efficacy and impact on rehospitalization of Qishen granules in patients with hypertension and heart failure with reduced ejection fraction: a multicenter, randomized, double-blind, placebo-controlled trial protocol"],"prefix":"10.3389","volume":"13","author":[{"given":"Fuyuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Postdoctoral Station of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorui","family":"Cui","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Xue","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global variations in heart failure etiology, management, and outcomes","volume":"329","author":"Rasmussen","year":"2023","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/00001573-200111000-00003","article-title":"Clinical aspects of hypertensive myocardial fibrosis","volume":"16","author":"Diez","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.cardfail.2021.05.023","article-title":"Drugs of abuse and heart failure","volume":"27","author":"Grubb","year":"2021","journal-title":"J Card Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","article-title":"Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms","volume":"69","author":"Hao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36949","DOI":"10.1038\/srep36949","article-title":"Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.phrs.2016.10.026","article-title":"Systems-biology dissection of mechanisms and chemical basis of herbal formula in treating chronic myocardial ischemia","volume":"114","author":"Guo","year":"2016","journal-title":"Pharmacol Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1017734","DOI":"10.3389\/fphar.2022.1017734","article-title":"The effects of qishen granules for patients with chronic heart failure: a multicenter randomized double-blind placebo-controlled trial","volume":"13","author":"Du","year":"2022","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e014240","DOI":"10.1161\/JAHA.119.014240","article-title":"Clinical implications of the New York heart association classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.hfc.2019.05.001","article-title":"Diagnosis and prevention of hypertensive heart failure","volume":"15","author":"Kalogeropoulos","year":"2019","journal-title":"Heart Fail Clin"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.3390\/ijms25126661","article-title":"Hypertension and heart failure: from pathophysiology to treatment","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jchf.2020.03.003","article-title":"The challenges of NT-proBNP testing in HFpEF: shooting arrows in the wind","volume":"8","author":"Januzzi","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ajem.2006.08.012","article-title":"Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure","volume":"25","author":"Di Somma","year":"2007","journal-title":"Am J Emerg Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e010107","DOI":"10.1161\/CIRCHEARTFAILURE.122.010107","article-title":"Comparing New York heart association class and patient-reported outcomes among patients hospitalized for heart failure","volume":"16","author":"Cosiano","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cjca.2019.08.020","article-title":"Sex differences in New York heart association functional classification and survival in acute heart failure patients with preserved or reduced ejection fraction","volume":"36","author":"Kajimoto","year":"2020","journal-title":"Can J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ejhf.3271","article-title":"Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction","volume":"26","author":"Wang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/bjsports-2021-105058","article-title":"Writing up your clinical trial report for a scientific journal: the REPORT trial guide for effective and transparent research reporting without spin","volume":"56","author":"Bandholm","year":"2022","journal-title":"Br J Sports Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1897966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:29Z","timestamp":1788759209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1897966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":22,"alternative-id":["10.3389\/fcvm.2026.1897966"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1897966","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1897966"}}